VCN Biosciences SL is a privately-owned company focused in the development of new therapeutic approaches for tumors that lack effective treatment. The company uses an oncolytic adenovirus technology platform to design highly selective and efficient agents that replicate and self-amplify exclusively in tumor cells. The selectivity of VCN oncolytic adenoviruses allows their systemic administration, which is especially relevant for the treatment of disseminated cancer. Contrary to chemotherapy, the ability of oncolytic virus to self-amplify in tumor cells results in an effective dose increase with time. These properties highlight VCN candidates as promising alternatives for the treatment of refractory tumors such as pancreatic adenocarcinomas, which is the current tumor target for VCN-01.
Mision
Development of new agents for the treatment of cancer based on oncolytic adenoviruses
Our science
Technological platform based on oncolytic adenoviruses to generate virotherapeutic candidates
Why VCN Biosciences
VCN Biosciences is a dynamic company passionate for cancer research
Pipeline
Virotherapy is a therapeutic approach for cancer treatment based on the use of viruses
News
VCN Biosciences Announces Publication in Peer-Reviewed Journal of Immunotherapy of Cancer on Clinical Data obtained with VCN-01 after intratumorally administration in patients with Pancreatic Cancer
VCN Biosciences Announces Publication in Peer-Reviewed Journal of Immunotherapy of Cancer on Clinical Data obtained with VCN-01 after intratumorally administration in patients with Pancreatic Cancer
Read more ...Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors
Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors
Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid TumorsLead drug candidate VCN-01 demonstrated clinical activity in multiple Phase 1 clinical trialsDesigned for systemic delivery, high selectivity, and enhanced tumor accessVCN-01 granted Orphan Drug Designation in Pancreatic Cancer by the EMASynthetic Biologics and VCN Biosciences to host a conference call today, December 14th, at 10:00 a.m. Eastern Time
For Immediate Release
Read more ...VCN Biosciences Announces Oral Presentation at IOVC 2021 on the latest Clinical Trial results of VCN-01 as a Novel Oncolytic Therapy Against Retinoblastoma
Barcelona, November 2nd, 2021.- VCN Biosciences, a clinical-stage immuno-oncology company focused on the development of the next generation of oncolytic adenoviruses, today announced the oral presentation at the upcoming 2021 International Oncolytic Virus Conference (IOVC) being held November 5-7, 2021, both virtually and in Sedona, Arizona.
Read more ...VCN Biosciences Announces Publication in Peer-Reviewed Journal of Controlled Release of Preclinical Research on an Oncolytic Adenovirus with Hyaluronidase Activity that Evades Neutralizing Antibodies
Barcelona, March 24, 2021.- VCN Biosciences, a clinical-stage immuno-oncology company focused on the development of the next generation of oncolytic adenoviruses, today announced the publication of preclinical research on promising therapy VCN-11 in Peer-Reviewed Journal of Controlled Release.
Read more ...© Copyright 2022 VCNBiosciences